Drug intelligence / Profile preview

apis mellifica + belladonna + radium bromatum

Development stage: Unknown
Administration: Oral, Sublingual

Overview

A homeopathic combination used primarily for preventing and treating radiodermatitis, a common side effect of radiotherapy in cancer treatment. This combination is specifically studied for use in breast cancer patients undergoing radiotherapy, where approximately 90% of patients experience radiodermatitis. Each component has specific properties: Apis mellifica (derived from honeybee) addresses swelling and inflammation, Belladonna helps with acute inflammatory conditions, and Radium bromatum specifically targets radiation-induced skin reactions.

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on apis mellifica + belladonna + radium bromatum.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on apis mellifica + belladonna + radium bromatum.

Explore the full profile